Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class...

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trials

Background:

• Talquetamab is an approved treatment for triple-class exposed (TCE) patients with relapsed/refractory multiple myeloma (RRMM).
• Real-world (RW) treatment effectiveness for TCE RRMM is not well-established.
• Comparative effectiveness of talquetamab versus RW physician's choice treatment needs evaluation.

Purpose of the Study:

• To compare the effectiveness of talquetamab against real-world physician's choice treatment in TCE RRMM patients.
• To assess progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS) for talquetamab versus RW treatment.

Main Methods:

• An external control arm was created using real-world data from the Flatiron Health database (n=629).
• Patient-level data from the MonumenTAL-1 study for talquetamab (0.4 mg/kg QW, n=143; 0.8 mg/kg Q2W, n=145) were included.
• Comparative effectiveness was assessed for PFS, TTNT, and OS after adjusting for baseline covariates.

Main Results:

• Talquetamab demonstrated significant improvements in PFS for both 0.4 mg/kg QW (median 7.5 vs. 4.0 months) and 0.8 mg/kg Q2W (median 14.2 vs. 4.0 months) schedules.
• Talquetamab significantly improved TTNT for both schedules (median 9.1 vs. 5.1 months and 13.3 vs. 5.1 months, respectively).
• Overall survival was significantly improved with talquetamab (0.4 mg/kg QW: median NR vs. 16.5 months; 0.8 mg/kg Q2W: median NR vs. 15.9 months).

Conclusions:

• Both talquetamab dosing schedules showed superior effectiveness compared to real-world treatment in TCE RRMM patients.
• Talquetamab represents an effective immunotherapy option for patients with TCE RRMM.